TABLE 2.
Percentages of subjects with hSBA titers ≥4 and rSBA titers ≥8 before and at 1, 2, 12, and 24 months after administration of Menitorix
| Parameter | Result for the following time (mo) after administration of Menitorix: |
||||
|---|---|---|---|---|---|
| 0 | 1 | 2 | 12 | 24 | |
| % of subjects with hSBA titer ≥4 | 16 (8/49)a | 94 (46/49) | 82 (37/45) | 31 (15/49) | 24 (12/49) |
| % of subjects with rSBA titer ≥8 | 31 (15/49) | 92 (46/50) | 92 (44/48) | 54 (27/50) | 30 (15/50) |
a
The data in parentheses indicate the number of subjects with the indicated titer/total number of subjects evaluated.